Gadoxetic Acid Disodium (Primovist, BAY86-4873)

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 23/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Diagnostic Imaging

Conditions

Diagnostic Imaging

Trial Timeline

Mar 11, 2008 → Feb 18, 2015

NCT ID

NCT01411449

About Gadoxetic Acid Disodium (Primovist, BAY86-4873)

Gadoxetic Acid Disodium (Primovist, BAY86-4873) is a pre-clinical stage product being developed by Bayer for Diagnostic Imaging. The current trial status is completed. This product is registered under clinical trial identifier NCT01411449. Target conditions include Diagnostic Imaging.

What happened to similar drugs?

3 of 6 similar drugs in Diagnostic Imaging were approved

Approved (3) Terminated (0) Active (3)

✅Remimazolam Tosilate for Injection + Remimazolam Tosilate for InjectionJiangsu Hengrui MedicineApproved

✅Xenetix + VisipaqueGuerbetApproved

✅IobitridolGuerbetApproved

🔄Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3

🔄Gadobutrol (Gadavist, Gadovist, BAY86-4875) + Gadoteridol (ProHance)BayerPhase 3

🔄Dotarem (gadoterate meglumine) + Magnevist (gadopentetate dimeglumine)GuerbetPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00908596	Approved	Completed	May 1, 2009	Jul 1, 2013	Contrast Media
NCT01411449	Pre-clinical	Completed	Mar 11, 2008	Feb 18, 2015	Diagnostic Imaging
NCT00924248	Pre-clinical	Completed	Oct 1, 2007	May 1, 2011	Liver
NCT00526188	Phase 3	Completed	Aug 1, 2007	Aug 1, 2008	Known or Suspected Focal Liver Lesions

Competing Products

11 competing products in Diagnostic Imaging

See all competitors

Product	Company	Stage	Hype Score
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)	Johnson & Johnson	Phase 3	40
Remimazolam Tosilate for Injection + Remimazolam Tosilate for Injection	Jiangsu Hengrui Medicine	Approved	39
Iopromide (Ultravist, BAY86-4877)	Bayer	Pre-clinical	23
BAY86-4367 + BAY86-4367	Bayer	Phase 1	18
F-18 DPA-714 (BAY85-8102) + F-18 DPA-714 (BAY85-8102) + F-18 DPA-714 (BAY85-8102)	Bayer	Phase 1	26
Ultravist (Iopromide, BAY86-4877)	Bayer	Pre-clinical	23
Gadopentetate dimeglumine (Magnevist, BAY86-4882)	Bayer	Pre-clinical	23
Gadobutrol (Gadavist, Gadovist, BAY86-4875) + Gadoteridol (ProHance)	Bayer	Phase 3	37
Xenetix + Visipaque	Guerbet	Approved	33
Iobitridol	Guerbet	Approved	33
Dotarem (gadoterate meglumine) + Magnevist (gadopentetate dimeglumine)	Guerbet	Phase 3	30